Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
about
Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysisChronic axial compression of the mouse tail segment induces MRI bone marrow edema changes that correlate with increased marrow vasculature and cellularity.Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Spondyloarthritides: evolving therapiesTreatment of ankylosing spondylitis with TNF blockers: a meta-analysis.TNF is required for the induction but not the maintenance of compression-induced BME signals in murine tail vertebrae: limitations of anti-TNF therapy for degenerative disc diseasePatient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabTNF-α and IL10 polymorphisms interaction increases the risk of ankylosing spondylitis in Chinese Han population.Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imagingTumor necrosis factor as a therapeutic target of rheumatologic disease.Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.Infliximab in the treatment of ankylosing spondylitis.Variables related to work productivity loss in patients with ankylosing spondylitis.Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis.The effect of total hip replacement on employment in patients with ankylosing spondylitis.Adaptation and validation of the Ankylosing Spondylitis Work Instability Scale (AS-WIS) for use in Turkey.Studies on correlation between single-nucleotide polymorphisms of tumor necrosis factor gene and different stages of ankylosing spondylitis.Predictors of presenteeism and activity impairment outside work in patients with spondyloarthritis.Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].
P2860
Q33936266-9E4F7CC3-2D3E-4CFD-8EE3-4E74BEBE9D99Q33936989-AA50BA32-F201-43AE-9F74-28A0BF86D361Q33990812-28AFD943-EE10-4ACB-ACD0-9C9BCA3E4BFFQ34613907-A68C25B7-6B07-44AF-BB3F-A4F0633F88C4Q34728162-960EEDDA-D659-40F8-91B8-CE4697DAB139Q34794168-D29A2160-154A-4C2D-8FA2-378BB2A5536FQ34803148-EC3A2564-137A-474B-A85A-D75DA2DE0454Q35759171-522A98F7-47A6-4A89-A1F3-FD2425735794Q36464908-7A1AEE3E-D747-4F23-9A5D-D8AF2DEC68B8Q36555104-1A5392DD-A8BD-4755-BCEB-2D3634F6656AQ36758296-4E952AB4-0E62-42C8-B316-FF37426F7B60Q36948874-838C8ED5-87DD-49E9-B88A-CD75E268956AQ37008829-8EC1FF81-87D9-4BDF-9A30-9455D9A1BCADQ37143025-707C9867-30B5-4AE9-8377-91BD2A9BECCDQ37172795-11CEB3E7-E6BE-4197-A356-8315ADB44A76Q37172804-79B97C14-348F-42E7-8CE9-55E3D2CD8043Q37290474-073569B4-5EE7-48D0-A05B-74064DFC645CQ38139808-29C42C19-9AE2-41DF-BBF8-4ECB48E2C765Q38191712-19481855-8C6C-415A-82BF-2496524A2F0DQ38198090-ACEFB6AB-3B70-4479-9837-79CE362AE701Q38901317-25AB5CAC-8EA9-4AAE-9C44-BE2AF5A3788EQ38980531-2DAD3547-3362-4946-BFC6-EA0FC546859DQ39297237-40896440-4128-47FD-BDDC-29B4E9FD1A29Q45736522-3B62D0A8-2EF1-46D2-A8C5-013FE7A7EFC3Q47994475-DF454F7A-A215-4991-9547-C2E1B570605CQ48066670-C520E636-7D82-41B6-A69C-044B7ED2B4DCQ48776801-B9BF566D-007F-4867-9690-E29BA70792E1Q52874129-2D24B3A6-D2B3-486B-8B5E-451A39082126
P2860
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Infliximab improves productivi ...... zed, placebo-controlled trial.
@en
Infliximab improves productivi ...... zed, placebo-controlled trial.
@nl
type
label
Infliximab improves productivi ...... zed, placebo-controlled trial.
@en
Infliximab improves productivi ...... zed, placebo-controlled trial.
@nl
prefLabel
Infliximab improves productivi ...... zed, placebo-controlled trial.
@en
Infliximab improves productivi ...... zed, placebo-controlled trial.
@nl
P2093
P356
P1476
Infliximab improves productivi ...... zed, placebo-controlled trial.
@en
P2093
Chenglong Han
Filip van den Bosch
Gerd Burmester
Jürgen Braun
Kirt DeVlam
Mohan Bala
Paul Williamson
P304
P356
10.1002/ART.22097
P577
2006-08-01T00:00:00Z